A common theme in my career has been research in the mechanism(s) of radiation resistance and of course the corollary trying to find ways to increase radiation sensitivity of resistant tumors. One of these basic work discovered the potential of Iressa to increase the radiation sensitivity for GBM cell lines; this idea was then translated from bench-to-bedside in a clinical protocol to treat brain metastases from NSCLCa with a similar combination of XRT + Tarceva (second generation TKI EGFR inhibitor).This work then resulted in a publication recently published in JCO. I believe this to be one of my most significant contribution to science simply on the basis of the progressive work from the bench to clinical application.
I am a professor of Radiation Oncology at the University of Arizona and the Head of the department.
I treat mainly brain tumors and do clinical research in the same field.

Reviewer Keywords